Breaking News
Active Shooter in Tactical Gear Storms Border Patrol Station in Texas--Cops Neutralize Attacker
Benjamin Franklin and the Self-Made Man: Making America
SHOCK REPORT: DOJ, FBI Review Finds NO Jeffrey Epstein 'Client List,' Confirms Suicide - SF6
FBI Concludes Jeffrey Epstein Had No Clients, Didn't Blackmail Anyone, And Definitely Killed Him
Top Tech News
Insulator Becomes Conducting Semiconductor And Could Make Superelastic Silicone Solar Panels
Slate Truck's Under $20,000 Price Tag Just Became A Political Casualty
Wisdom Teeth Contain Unique Stem Cell That Can Form Cartilage, Neurons, and Heart Tissue
Hay fever breakthrough: 'Molecular shield' blocks allergy trigger at the site
AI Getting Better at Medical Diagnosis
Tesla Starting Integration of XAI Grok With Cars in Week or So
Bifacial Solar Panels: Everything You NEED to Know Before You Buy
INVASION of the TOXIC FOOD DYES:
Let's Test a Mr Robot Attack on the New Thunderbird for Mobile
Facial Recognition - Another Expanding Wolf in Sheep's Clothing Technology
CBD Bombshell:
This is huge. The FDA just granted orphan drug designation (ODD) to Insys Therapeutics for its pharmaceutical-grade, proprietary cannabidiol (CBD) product for treating cancer tumors in humans. Although glioma tumors affect less than 200,000 Americans, this FDA approval sets a precedent for natural remedies, and could lead to a revolutionary way to legally treat many forms of cancer with natural cures. In justifying preliminary approval of utilizing CBD to treat brain and spinal cancer tumors of this kind, Insys Therapeutics provided the FDA with the scientific rationale for CBD's benefits, including human experiences with the natural remedy, evidence discovered through in vitro studies, and preclinical animal testing.